作者
Peter Malfertheiner, Francis Megraud, Theodore Rokkas, Javier P Gisbert, Jyh-Ming Liou, Christian Schulz, Antonio Gasbarrini, Richard H Hunt, Marcis Leja, Colm O'Morain, Massimo Rugge, Sebastian Suerbaum, Herbert Tilg, Kentaro Sugano, Emad M El-Omar
发表日期
2022/9/1
期刊
Gut
卷号
71
期号
9
页码范围
1724-1762
出版商
BMJ Publishing Group
简介
Helicobacter pylori
Infection is formally recognised as an infectious disease, an entity that is now included in the International Classification of Diseases 11th Revision. This in principle leads to the recommendation that all infected patients should receive treatment. In the context of the wide clinical spectrum associated with Helicobacter pylori gastritis, specific issues persist and require regular updates for optimised management.
The identification of distinct clinical scenarios, proper testing and adoption of effective strategies for prevention of gastric cancer and other complications are addressed. H. pylori treatment is challenged by the continuously rising antibiotic resistance and demands for susceptibility testing with consideration of novel molecular technologies and careful selection of first line and rescue therapies. The role of H. pylori and antibiotic therapies and their impact on the gut microbiota are also …
引用总数
2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320243291515191487665510153234452331261